Consistent efficacy outcomes between phase 2 and phase 3 trials in Crohn’s disease or ulcerative colitis in adults: a meta-analysis
Inflammation Research · 2024
DOI: 10.1007/s00011-024-01874-9 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Inflammation Research, 2024. Verfasst von Ziqi Wan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, C…. Hauptthemen laut MEDLINE: Crohn Disease, Colitis, Ulcerative, Clinical Trials, Phase III as Topic, Clinical Trials, Phase II as Topic. Die Arbeit nennt 79 Literaturangaben. Gefördert von: Peking Union Medical College Teaching Reform in Undergraduate Education, National Key R&D Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
INTRODUCTION: The approval of novel biologic agents and small molecules for the treatment of Crohn's disease (CD) and ulcerative colitis (UC) is dependent on phase 3 randomized controlled trials (RCTs). However, these trials sometimes fail to achieve the expected efficacy outcomes observed in phase 2 trials. METHODS: We conducted a systematic review of RCTs that evaluated biologic agents and small molecules using paired regimens in both phase 2 and phase 3. We searched Medline, EMBASE, and Cochrane databases up until February 13, 2024. The revised Cochrane tool was utilized to assess the risk of bias. A generalized linear mixed-effects model (GLMM) was employed to estimate the odds ratios (ORs) for efficacy outcomes in phase 2 trials compared to phase 3. RESULTS: We identified a total of 23 trials with 10 paired regimens for CD and 30 trials with 11 paired regimens for UC. The GLMM analysis revealed that phase 2 CD trials had higher outcomes measured by the Crohn's Disease Activity Index (CDAI) by 9-13% without statistical significance: CDAI-150: OR, 1.12 (95% CI 0.83-1.51, p = 0.41); CDAI-100: OR, 1.09 (95% CI 0.88-1.35, p = 0.40); or CDAI-70: OR, 1.13 (95% CI 0.61-2.08, p = 0.66). For UC, two efficacy outcomes were estimated to be equally reported in phase 2/phase 3 pairs: clinical remission: OR, 1.00 (95% CI 0.83-1.20, p = 0.96); endoscopic improvement: OR, 0.98 (95% CI 0.83-1.15, p = 0.79). However, the rate of clinical response was underestimated in phase 2 by 19%: OR, 0.81 (95% CI 0.70-0.95, p = 0.03). The inclusion criterion for the type of Mayo score for UC had a significant interaction with the study phase to influence the difference in clinical response (p = 0.002). CONCLUSIONS: Our findings suggest that the main efficacy outcomes for CD and UC remain consistent between phase 2 and phase 3 trials, except for UC response rates. The efficacy data obtained from phase 2 trials can be considered reliable for the design of subsequent phase 3 trials. REGISTRATION: PROSPERO (CRD42023407947).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Eight-Year Program, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
- Vanke School of Public Health, Tsinghua University, Beijing, China.
- Institute of Basic Medical Sciences, School of Basic Medicine, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. baixiaoyin@pumch.cn.
- Vanke School of Public Health, Tsinghua University, Beijing, China. guanqiaoli@tsinghua.edu.cn.
Förderung
- Peking Union Medical College Teaching Reform in Undergraduate Education
- National Key R&D Program of China
- National Natural Science Foundation of China
- National High Level Hospital Clinical Research Funding
- National Key Clinical Specialist Construction Project
Zitieren
APA
Wan, Z., Jiang, Q., Zhou, R., Li, X., Han, W., Xu, B., Guo, M., Ruan, G., Bai, X., Li, G., & Yang, H. (2024). Consistent efficacy outcomes between phase 2 and phase 3 trials in Crohn’s disease or ulcerative colitis in adults: a meta-analysis. Inflammation Research. https://doi.org/10.1007/s00011-024-01874-9
Vancouver
Wan Z, Jiang Q, Zhou R, Li X, Han W, Xu B, et al. Consistent efficacy outcomes between phase 2 and phase 3 trials in Crohn’s disease or ulcerative colitis in adults: a meta-analysis. Inflammation Research. 2024. doi:10.1007/s00011-024-01874-9
BibTeX
@article{Wan2024,
author = {Wan, Ziqi and Jiang, Qingwei and Zhou, Runing and Li, Xiang and Han, Wei and Xu, Bing and Guo, Mingyue and Ruan, Gechong and Bai, Xiaoyin and Li, Guanqiao and Yang, Hong},
title = {Consistent efficacy outcomes between phase 2 and phase 3 trials in Crohn’s disease or ulcerative colitis in adults: a meta-analysis},
journal = {Inflammation Research},
year = {2024},
doi = {10.1007/s00011-024-01874-9}
}
EUVIMED